Printer Friendly

DISEASE DETECTION INTERNATIONAL TO SUPPLY 1.2 MILLION TESTS IN BRASILIAN FEDERAL AIDS PROGRAM FOR THE STATE OF SAO PAULO, BRASIL

 IRVINE, Calif., Sept. 20 /PRNewswire/ -- Disease Detection International, Inc. (DDI) (NASDAQ OTC Bulletin Board: DDII) announced today the company has received notice from its Brasilian joint venture, DDI do Brasil, that the companies have been awarded a federal order for 1.2 million SeroCard(R) HIV-1 tests to be used by the Government of Sao Paulo, through the Department of Health, in a program for testing low income populations. DDI do Brasil indicated that the order for 1.2 million AIDS tests is an interim order scheduled for delivery in October, November and December 1993, with follow-on deliveries expected through 1994 as wide scale testing of the 30 million inhabitants in the state of Sao Paulo is instituted.
 H. Thad Morris, president and CEO of DDI, announced the receipt of the news from Brasil during the company's annual shareholders meeting on Friday, Sept. 17, 1993. "Perhaps more important than the prospect of up to $4 million in additional revenue for DDI's fourth quarter, is the fact that we have been selected to participate in such a bold and courageous effort by health authorities in this portion of Brasil to educate and test its people. The SeroCard HIV, seven minute, whole blood test is fast, accurate, simple to perform and represents one of the most cost effective means to assess one's immune status. For every one million people tested, our patented format represents more than $2 million in savings just in collecting the sample from a finger stick rather than venipuncture and sample preparation. Additional savings compared to conventional testing methods exists in that instrumentation is not required to perform our test; a significant factor for counties with limited resources in smaller cities and remote villages."
 Mr. Morris further stated that the SeroCard HIV tests will be manufactured and shipped by DDI from its Mexico contract manufacturer and supplemented, if necessary, by production available through our licensee Trinity Biotech plc (ADRs-NASDAQ: HIVSY) of Dublin, Ireland. The company plans to establish additional manufacturing capacity under future licensing arrangements with DDI do Brasil during the early part of 1994. "Our ultimate goal is to manufacture under license in the markets we serve to offset freight, import duties and other costs which impact the cost of healthcare products. In addition, we can become true partners in providing jobs at the local level and encourage continued development of a variety of diagnostic tests which are of particular significance to the populations we serve. As a 49 percent shareholder in DDI do Brasil and 12 percent shareholder in Trinity Biotech, we will benefit from their success in assisting us to meet the demand anticipated for AIDS testing in Central and South America."
 Disease Detection International, Inc., develops, manufactures and markets a family of patented, rapid diagnostic tests for infectious and sexually transmitted diseases and for the detection of pregnancy and fertility.
 -0- 9/20/93
 /CONTACT: Tom Dean of Innovative Research Associates, 212-421-2543, or H. Thad Morris, president and CEO of Disease Detection International, 714-457-1787/
 (DDII)


CO: Disease Detection International, Inc. ST: California IN: MTC SU:

SM-TS -- NY019 -- 3517 09/20/93 09:29 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 20, 1993
Words:519
Previous Article:APC GAINS ISO9000 STATUS ON QUALITY PROGRAMS, WINS SUPPLIER OF EXCELLENCE AWARD FROM UNISYS
Next Article:TI TO REDEEM $149.6 MILLION PREFERRED STOCK
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters